Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.

Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB.

Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21.

PMID:
31113840
2.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

3.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A.

Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.

4.

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N, Ribas A.

Cancer Immunol Res. 2017 Feb;5(2):118-126. doi: 10.1158/2326-6066.CIR-16-0148. Epub 2016 Dec 30.

5.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

6.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

7.

PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A.

Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.

8.

Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial.

Ito A, Shintaku I, Satoh M, Ioritani N, Tochigi T, Numata I, Namima T, Kambe K, Kyan A, Ueno S, Katoh S, Adachi H, Yamashita S, Yamaguchi T, Arai Y; Tohoku Urological EBM Study Group.

Jpn J Clin Oncol. 2013 Nov;43(11):1139-44. doi: 10.1093/jjco/hyt129. Epub 2013 Sep 4.

PMID:
24006504
9.

Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y.

J Clin Oncol. 2013 Apr 10;31(11):1422-7. doi: 10.1200/JCO.2012.45.2128. Epub 2013 Mar 4.

PMID:
23460707
10.

Suprapubic versus transurethral bladder drainage after radical prostatectomy: impact on patient discomfort.

Orikasa S, Kanbe K, Shirai S, Shintaku I, Kurosu S.

Int J Urol. 2012 Jun;19(6):587-90. doi: 10.1111/j.1442-2042.2012.02980.x. Epub 2012 Mar 8.

11.

Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY, Apple SK.

Am J Clin Pathol. 2011 Nov;136(5):754-61. doi: 10.1309/AJCP99WZGBPKCXOQ.

PMID:
22031314
12.

Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma.

Mendelsohn AH, Lai CK, Shintaku IP, Fishbein MC, Brugman K, Elashoff DA, Abemayor E, Dubinett SM, St John MA.

Am J Otolaryngol. 2012 Jan-Feb;33(1):6-13. doi: 10.1016/j.amjoto.2010.11.018. Epub 2011 Mar 24.

13.

The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma.

Apple S, Pucci R, Lowe AC, Shintaku I, Shapourifar-Tehrani S, Moatamed N.

Am J Clin Pathol. 2011 Apr;135(4):592-8. doi: 10.1309/AJCPB1RIT5YXMRIS.

PMID:
21411782
14.

Histopathologic findings of HPV and p16 positive HNSCC.

Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, St John MA.

Laryngoscope. 2010 Sep;120(9):1788-94. doi: 10.1002/lary.21044.

PMID:
20803740
15.

Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer.

Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA.

Mod Pathol. 2009 Sep;22(9):1151-9. doi: 10.1038/modpathol.2009.82. Epub 2009 May 29.

16.

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ.

Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783.

17.

Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.

Shintaku I, Satoh M, Okajima E, Fujimoto H, Kamoto T, Ogawa O, Kawai K, Akaza H, Tsukamoto T, Naito S, Miki T, Arai Y.

Jpn J Clin Oncol. 2008 Apr;38(4):281-7. doi: 10.1093/jjco/hyn009. Epub 2008 Mar 4.

PMID:
18321891
18.

Acute renal failure as a result of bilateral ureteral obstruction by Candida albicans fungus balls.

Shimada S, Nakagawa H, Shintaku I, Saito S, Arai Y.

Int J Urol. 2006 Aug;13(8):1121-2.

19.

Distribution of class I and II human leukocyte antigens in the larynx.

Wang EC, Damrose EJ, Mendelsohn AH, Nelson SD, Shintaku IP, Ye M, Berke GS, Blackwell KE.

Otolaryngol Head Neck Surg. 2006 Feb;134(2):280-7.

PMID:
16455378
20.

Prostate stem cell antigen is overexpressed in prostate cancer metastases.

Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE.

Clin Cancer Res. 2005 Apr 1;11(7):2591-6.

21.

An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas.

Hoyer KK, Pang M, Gui D, Shintaku IP, Kuwabara I, Liu FT, Said JW, Baum LG, Teitell MA.

Am J Pathol. 2004 Mar;164(3):893-902.

22.

Health-related quality of life after radical prostatectomy in Japanese men with localized prostate cancer.

Namiki S, Tochigi T, Kuwahara M, Ohnuma T, Ioritani N, Soma F, Shintaku I, Terai A, Nakagawa H, Satoh M, Saito S, Koinuma N, Arai Y.

Int J Urol. 2003 Dec;10(12):643-50.

23.

Urethral recurrence following neobladder in bladder cancer patients.

Yamashita S, Hoshi S, Ohyama C, Satoh M, Soma F, Okada Y, Kato S, Shintaku I, Arai Y.

Tohoku J Exp Med. 2003 Apr;199(4):197-203.

24.

Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients.

Hoshi S, Jokura H, Nakamura H, Shintaku I, Ohyama C, Satoh M, Saito S, Fukuzaki A, Orikasa S, Yoshimoto T.

Int J Urol. 2002 Nov;9(11):618-25; discussion 626; author reply 627.

25.

[Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy].

Shintaku I, Numahata K, Suzuki K, Ohyama C, Sato M, Saito S, Hoshi S, Orikasa S.

Nihon Hinyokika Gakkai Zasshi. 2002 May;93(4):519-24. Japanese.

26.

Adrenal metastasis from renal cell carcinoma: significance of adrenalectomy.

Ito A, Satoh M, Ohyama C, Saito S, Shintaku I, Nakano O, Aoki H, Hoshi S, Orikasa S.

Int J Urol. 2002 Mar;9(3):125-8.

27.

Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H.

Cancer Res. 2001 Jul 1;61(13):5132-6.

28.

Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years.

Hoshi S, Shintaku I, Suzuki K, Takahashi T, Kaihou Y, Ishidoya S, Namima T, Ohyama C, Orikasa S.

Tohoku J Exp Med. 2000 Dec;192(4):249-58.

29.

Two patients with N3 bladder cancer successfully treated by internal iliac arterial infusion chemotherapy and irradiation: case reports.

Hoshi S, Suzuki KI, Shintaku I, Sato K, Kaihou Y, Namima T, Satoh M, Ohyama C, Orikasa S.

Am J Clin Oncol. 2001 Feb;24(1):87-90.

PMID:
11232958
30.

Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.

Lones MA, Kirov I, Said JW, Shintaku IP, Neudorf S.

Bone Marrow Transplant. 2000 Nov;26(9):1021-4. Review.

31.

Expression of the SART3 tumor rejection antigen in renal cell carcinoma.

Kawagoe N, Shintaku I, Yutani S, Etoh H, Matuoka K, Noda S, Itoh K.

J Urol. 2000 Dec;164(6):2090-5.

PMID:
11061933
32.

Expression of the SART1 tumor rejection antigen in renal cell carcinoma.

Shintaku I, Kawagoe N, Yutani S, Hoshi S, Orikasa S, Yoshizumi O, Itoh K.

Urol Res. 2000 Jun;28(3):178-84.

PMID:
10929426
33.

Relationship between regional cardiac hyperinnervation and ventricular arrhythmia.

Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, Chen PS, Chen LS.

Circulation. 2000 Apr 25;101(16):1960-9.

PMID:
10779463
34.

[Characteristics of incidentally detected renal cell carcinoma by ultrasonography at health check-up].

Shintaku I, Suzuki Y, Uchi K, Morita M, Terasawa Y.

Nihon Hinyokika Gakkai Zasshi. 2000 Feb;91(2):43-8. Japanese.

35.

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.

Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE.

Oncogene. 2000 Mar 2;19(10):1288-96.

36.

Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T-cell phenotype.

Said JW, Shintaku IP, Asou H, deVos S, Baker J, Hanson G, Cesarman E, Nador R, Koeffler HP.

Arch Pathol Lab Med. 1999 Mar;123(3):257-60.

PMID:
10086517
37.
38.

Alterations in fascin-expressing germinal center dendritic cells in neoplastic follicles of B-cell lymphomas.

Said JW, Pinkus JL, Shintaku IP, deVos S, Matsumura F, Yamashiro S, Pinkus GS.

Mod Pathol. 1998 Jan;11(1):1-5.

PMID:
9556415
39.

Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.

Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, Berenson JR.

Blood. 1997 Dec 1;90(11):4278-82.

PMID:
9373238
40.

Donor origin of posttransplant lymphoproliferative disorder localized to a liver allograft: demonstration by fluorescence in situ hybridization.

Lones MA, Lopez-Terrada D, Weiss LM, Shintaku IP, Said JW.

Arch Pathol Lab Med. 1997 Jul;121(7):701-6.

PMID:
9240905
41.

Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus.

Lones MA, Shintaku IP, Weiss LM, Thung SN, Nichols WS, Geller SA.

Hum Pathol. 1997 May;28(5):533-9.

PMID:
9158700
43.

Anterior urethral diverticulum produced by Cowper's gland duct cyst.

Shintaku I, Ono Y, Katoh N, Takeda A, Ohshima S.

Int J Urol. 1996 Sep;3(5):412-3.

44.

Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells.

Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J, Shintaku IP, Krajewski S, Reed JC, Binderup L, Koeffler HP.

Cancer Res. 1996 Aug 1;56(15):3570-6.

45.

mdm-2 oncogene expression in non-Hodgkin's lymphomas.

Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW.

Diagn Mol Pathol. 1996 Mar;5(1):33-8.

PMID:
8919543
46.

[Retroperitoneal laparoscopic nephrectomy: initial 2 cases].

Katoh N, Ono Y, Yamada S, Mizutani K, Shintaku I, Ohshima S.

Nihon Hinyokika Gakkai Zasshi. 1996 Jan;87(1):13-7. Japanese.

47.

20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.

Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP.

Cancer Res. 1995 Jul 1;55(13):2822-30.

48.
49.

Bcl-2 oncogene protein is preferentially expressed in Reed-Sternberg cells in Hodgkin's disease of the nodular sclerosis subtype.

Lones MA, Pinkus GS, Shintaku IP, Said JW.

Am J Clin Pathol. 1994 Oct;102(4):464-7.

PMID:
7524301
50.

Supplemental Content

Loading ...
Support Center